Skip to main content

Cornell, Hebrew University, Tel Aviv University, and Stanford Complete Licensing Deals

Following is a summary of notable biotechnology and life sciences licensing deals announced last week between academic or non-profit research institutions and private entities:
Licensing Institution: Cornell University
Primary Inventor: John Savarese, chairman, department of anesthesiology, Weill Cornell Medical Center
Licensee: Avera Pharmaceuticals, San Diego
Technology: Avera has licensed two compounds from Cornell. The first, AV002, is an intermediate-acting, non-depolarizing, neuromuscular blocking compound in late preclinical development as a surgical muscle relaxant. The second compound is a preoprietary reversal agent that reverses neuromuscular blockade.

Licensing Institutions: Hebrew University of Jerusalem and Tel Aviv University, Israel
Primary Inventors: Hillel Bercovier and Ayelet Barenholz, professors, Hebrew University; and Jonathan Gershoni, professor, Tel Aviv University
Licensee: BioLineRx, Jerusalem, Israel
Technology: BL-4020, a peptide designed to function as an anti-inflammatory agent in various inflammatory diseases such as allergic asthma and colitis. The peptide mimics ManLAM, a protein from the cell surface of Mycobacterium tuberculosis.

Licensing Institution: Stanford University School of Medicine, Stanford, CA
Primary Inventor: Michelle Calos, associate professor of genetics, Stanford University School of Medicine
Licensee: Pain Therapeutics
Technology: Gene integration technology that may be able to replace daily or weekly protein replacement therapy with a single, lasting procedure that promotes normal blood coagulation in hemophilic patients.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.